$NP

NP Maintained by Morgan Stanley -- Price Target Lowered to $35.0

Morgan Stanley maintained an Overweight rating on Neptune Insurance Holdings (NP) but lowered its price target to $35.00 from $36.00. The company's P/E ratio is 127.05x, above its 5-year median. Insider activity shows significant selling. NP operates in climate-related property insurance with a market cap of $3.99 billion.

Original reporting
Published Oct 22, 2026, 6:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 7:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$NP
Bearish
medium confidence
Mentioned
$NP
Relevance
6/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$NPBearishMed
01

Why it matters

Analyst target cut reflects concerns over valuation and growth, potentially prompting short‑term price weakness.

02

Market read

NP's price‑target reduction is the primary actionable item; broader sector impact is modest.

03

What to watch

Insider sell volume is large; however, the GF score shows weak growth and momentum, which may limit recovery.

Relevance 6/10Novelty 5/10Timing: today

Background

NP is a managing general agent focused on climate‑related property risks with a market cap of ~$4 bn.

Company-level read

Ticker impact

$NPBearishMedium confidence
Context

Morgan Stanley lowered NP's price target to $35 from $36, indicating a more cautious valuation.

Expected impact

likely pressure as the market prices in the lower target

Evidence & confidence

Analyst price‑target reductions typically lead to short‑term sell pressure, especially with a high P/E and weak GF score.

Market effects

The downgrade may weigh on other climate‑focused insurers and specialty property insurers.

Limited to U.S. specialty insurance sector.

Low global impact; primarily a stock‑specific move.

Counterpoint

The high P/E could still justify upside if climate‑risk pricing improves.

Key entities

  • Morgan Stanley

    Maintained Overweight rating but lowered price target.

Related articles

$NPHighAI 8/10

Mizuho raises Neptune Insurance stock price target to $33 on guidance

Mizuho raised its price target on Neptune Insurance (NYSE:NP) to $33 from $31, maintaining a Neutral rating. The company reported adjusted EPS of $0.17, up 44% YoY, and raised fiscal 2026 revenue guidance to $204M. Revenue grew 34% YoY, and adjusted EBITDA margin improved to 61.7%. Management also introduced fiscal 2027 guidance of $238M. InvestingPro data shows the stock trades above Fair Value.

$NPMed

Neptune Insurance Holdings Inc (NP) (Q3 2026) Earnings Call Highlights: Record EBITDA

Neptune Insurance (NP) reported record EBITDA in Q3 2026, raising 2026 guidance and providing initial 2027 outlook. CEO Trevor Burgess highlighted AI's potential to reduce costs, deep distribution relationships, and competitive advantages in the flood market. The company expects margin growth, driven by AI and new products like an upcoming earthquake offering. Strong new business premium growth was attributed to expanding into underinsured markets.

$NPHigh

Neptune Insurance Holdings Inc. Reports Third Quarter 2026 Results

Neptune Insurance Holdings Inc. (NP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Neptune Insurance Holdings Inc. Reports Third Quarter 2026 Results ST. PETERSBURG, Fla., Oct 20, 2026 – Neptune Insurance Holdings Inc. (the “Company”) (NYSE: NP), the parent company of Neptune Flood Incorporated, has released its financial results for the third quarter of 2026 b

$JNJMed

Johnson & Johnson Reports Early JNJ-6143 Responses in Prostate Cancer Trial

Johnson & Johnson reported positive results for its investigational drug JNJ-6143 in a Phase 1 prostate cancer trial, with 77% of patients showing a confirmed PSA decline. The company selected a 50-mg daily dose for Phase 2 testing. The drug is designed to target the androgen receptor and BRD4 protein. Johnson & Johnson acquired Halda Therapeutics, the drug's original developer, for $3.05 billion in 2025.